Abstract
Ascidians (tunicates; sea squirts) are marine animals which provide a source of diverse, bioactive natural products, and a model for toxicity screenings. Compounds isolated from ascidians comprise an approved anti-tumor drug and many others are potent drug leads. Furthermore, the use of invertebrate embryos for toxicological screening tests or analysis offers the possibility to image a large number of samples for high throughput screens. Ascidians are members of a sister clade to the vertebrates and make a vertebrate-like tadpole larva composed of less than 3000 cells in 18 hours. The neural complex of the ascidian larva is made of only 350 cells (of which 100 are neurons) and functional genomic studies have now uncovered numerous GRNs underpinning neural specification and differentiation. Numerous studies showed that brain formation in ascidians is sensitive to toxic insults especially from endocrine disruptors making them a suitable model to study neurodevelopmental defects. Modern techniques available for ascidians, including transgenic embryos where 3D time lapse imaging of GFPexpressing reporter constructs can be analyzed, now permit numerous end-points to be evaluated in order to test the specific mode of action of many compounds. This review summarizes the key evidence suggesting that ascidian embryos are a favorable embryological model to study neurodevelopmental toxicity of different compounds with molecular and cellular end-points. We predict that ascidians may become a significant source of marine blue biotechnologies in the 21st century.
Keywords: Tunicates, Embryonic development, Neurodevelopmental toxicity, Blue biotechnologies, Screening, GRNs.
Current Topics in Medicinal Chemistry
Title:Ascidians: An Emerging Marine Model for Drug Discovery and Screening
Volume: 17 Issue: 18
Author(s): Remi Dumollard*, Ievgeniia Gazo, Isa D. L. Gomes, Lydia Besnardeau and Alex McDougall
Affiliation:
- Sorbonne Universités, UPMC Univ. Paris 06, CNRS, Laboratoire de Biologie du Dévelopement de Villefranche- sur-mer (LBDV), Observatoire Oceanologique, 06230, Villefranche sur-mer,France
Keywords: Tunicates, Embryonic development, Neurodevelopmental toxicity, Blue biotechnologies, Screening, GRNs.
Abstract: Ascidians (tunicates; sea squirts) are marine animals which provide a source of diverse, bioactive natural products, and a model for toxicity screenings. Compounds isolated from ascidians comprise an approved anti-tumor drug and many others are potent drug leads. Furthermore, the use of invertebrate embryos for toxicological screening tests or analysis offers the possibility to image a large number of samples for high throughput screens. Ascidians are members of a sister clade to the vertebrates and make a vertebrate-like tadpole larva composed of less than 3000 cells in 18 hours. The neural complex of the ascidian larva is made of only 350 cells (of which 100 are neurons) and functional genomic studies have now uncovered numerous GRNs underpinning neural specification and differentiation. Numerous studies showed that brain formation in ascidians is sensitive to toxic insults especially from endocrine disruptors making them a suitable model to study neurodevelopmental defects. Modern techniques available for ascidians, including transgenic embryos where 3D time lapse imaging of GFPexpressing reporter constructs can be analyzed, now permit numerous end-points to be evaluated in order to test the specific mode of action of many compounds. This review summarizes the key evidence suggesting that ascidian embryos are a favorable embryological model to study neurodevelopmental toxicity of different compounds with molecular and cellular end-points. We predict that ascidians may become a significant source of marine blue biotechnologies in the 21st century.
Export Options
About this article
Cite this article as:
Dumollard Remi*, Gazo Ievgeniia, Gomes D. L. Isa, Besnardeau Lydia and McDougall Alex, Ascidians: An Emerging Marine Model for Drug Discovery and Screening, Current Topics in Medicinal Chemistry 2017; 17 (18) . https://dx.doi.org/10.2174/1568026617666170130104922
DOI https://dx.doi.org/10.2174/1568026617666170130104922 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurokinin Receptors as Potential Targets in Breast Cancer Treatment
Current Drug Discovery Technologies Carbon Nanotubes as an Advanced Drug and Gene Delivery Nanosystem
Current Nanoscience Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
Current Drug Targets Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Triacylglycerol Metabolism
Current Drug Targets Impact of Genetic Polymorphisms and Drug – Drug Interactions on Clopidogrel and Prasugrel Response Variability
Current Drug Metabolism Prospecting for New Inhibitors of Anaplastic Lymphoma Kinase, A Clinically Relevant Oncogenic Drug Target
Current Bioactive Compounds Fluoride Interactions: From Molecules to Disease
Current Signal Transduction Therapy Oxytocin Release: A Remedy for Cerebral Inflammaging
Current Aging Science Diabetic Papillopathy: Current and New Treatment Options
Current Diabetes Reviews Nutrition in Adult Patients with Inflammatory Bowel Disease
Current Drug Targets Immunization Against Active Ghrelin Using Virus-Like Particles for Obesity Treatment
Current Pharmaceutical Design Stevia as a Natural Sweetener: A Review
Cardiovascular & Hematological Agents in Medicinal Chemistry Meet Our Associate Editor
Applied Clinical Research, Clinical Trials and Regulatory Affairs A Rare Diagnosis After the Fall of a 96-Year-Old Woman: Doege-Potter Syndrome
Current Aging Science Protective Effect of Alpha-Tocopherol in Deltamethrin Induced Immunotoxicity
Endocrine, Metabolic & Immune Disorders - Drug Targets P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Editorial (Thematic Issue: Biological Toxins and Medicinal Chemistry: Research and Therapeutic Tools)
Current Topics in Medicinal Chemistry PCSK9 Inhibition - A Novel Mechanism to Treat Lipid Disorders?
Current Pharmaceutical Design Targeting Metabolism to Counteract Tumor Angiogenesis: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery